Qiagen stock rises on 2025 results and 2026 guidance

Qiagen (ISIN NL0012169213) stock is anchored by 2025 revenue of $2.04 billion and adjusted diluted EPS of $1.94, while management guided to about 4% sales growth in 2026 on a constant-currency basis. The latest figures frame the shares around a business that still generates scale, margin, and cash flow even as the top line reset in 2025.

2025 revenue and EPS

Qiagen reported full-year 2025 net sales of $2.04 billion, down 5% in constant currency versus 2024, according to the companys annual results. Adjusted diluted earnings per share for 2025 were $1.94, and adjusted operating income was $657 million, giving the year a clear profit base even after the lower revenue line.

The same results showed adjusted EBITDA of $747 million in 2025, with an adjusted EBITDA margin of 36.6%. That margin is the most useful number in the set because it shows how much of the sales base converted into operating earnings during a year of weaker currency-adjusted demand.

2026 guidance points higher

For 2026, Qiagen guided to about 4% sales growth at constant exchange rates and adjusted diluted EPS of about $2.35. The company also projected adjusted operating income of about $710 million, which would mark a step up from the $657 million reported for 2025.

Managements outlook implies a bigger profit line than the prior year, with adjusted diluted EPS rising from $1.94 to about $2.35. That is a difference of roughly 21%, a concrete comparison that makes the guidance more important than the headline growth rate alone.

Cash flow still matters

Qiagen said it delivered adjusted free cash flow of $560 million in 2025. That figure matters because it gives the company room to fund operations, investment, and capital returns even while the sales trend is still rebuilding.

The 2025 result also showed adjusted gross margin at 67.1%, which helps explain why earnings stayed resilient relative to the revenue decline. For investors following the shares, the margin line is now as important as the pace of recovery in sales.

QIAstat-DX and QIAsymphony

Qiagens product mix still revolves around sample preparation and molecular diagnostics platforms such as QIAstat-DX and QIAsymphony. Those systems sit at the center of the companys recurring consumables model, where installed base and reagent pull-through matter more than one-off instrument sales.

The business relevance of that model shows up in the 2025 numbers: $2.04 billion in net sales, $747 million in adjusted EBITDA, and $560 million in adjusted free cash flow. Together those figures suggest the portfolio is designed to keep earnings and cash generation steadier than the revenue line might imply at first glance.

Stock context

Qiagen shares on Nasdaq, as the company is listed in New York in the form of American depositary shares. The price level is not reproduced here because the available evidence in this call centers on the companys 2025 results and 2026 guidance, not a fresh exchange quote.

That leaves the most recent report metrics as the cleaner market reference point: $2.04 billion revenue in 2025, $1.94 adjusted diluted EPS, and about $2.35 guided for 2026. The comparison between those two EPS figures is the clearest near-term change in the set.